Show simple item record

dc.contributor.authorBOWIE, ANDREWen
dc.date.accessioned2010-08-18T12:41:53Z
dc.date.available2010-08-18T12:41:53Z
dc.date.issued2005en
dc.date.submitted2005en
dc.identifier.citationStack, J. Haga, I.R., Schroeder, M., Bartlett, N.W., Maloney, G., Reading, P.C., Fitzgerald, K.A., Smith, G.L. & Bowie, A.G, Vaccinia virus protein A46R targets multiple Toll-like-interleukin-1 receptor adaptors and contributes to virulence, The Journal of Experimental Medicine, 201, 6, 2005, 1007 - 1018en
dc.identifier.otherYen
dc.descriptionPUBLISHEDen
dc.descriptionPMID: 15767367en
dc.description.abstractViral immune evasion strategies target key aspects of the host antiviral response. Recently, it has been recognized that Toll-like receptors (TLRs) have a role in innate defense against viruses. Here, we define the function of the vaccinia virus (VV) protein A46R and show it inhibits intracellular signalling by a range of TLRs. TLR signalling is triggered by homotypic interactions between the Toll-like?interleukin-1 resistance (TIR) domains of the receptors and adaptor molecules. A46R contains a TIR domain and is the only viral TIR domain?containing protein identified to date. We demonstrate that A46R targets the host TIR adaptors myeloid differentiation factor 88 (MyD88), MyD88 adaptor-like, TIR domain?containing adaptor inducing IFN-? (TRIF), and the TRIF-related adaptor molecule and thereby interferes with downstream activation of mitogen-activated protein kinases and nuclear factor ?B. TRIF mediates activation of interferon (IFN) regulatory factor 3 (IRF3) and induction of IFN-? by TLR3 and TLR4 and suppresses VV replication in macrophages. Here, A46R disrupted TRIF-induced IRF3 activation and induction of the TRIF-dependent gene regulated on activation, normal T cell expressed and secreted. Furthermore, we show that A46R is functionally distinct from another described VV TLR inhibitor, A52R. Importantly, VV lacking the A46R gene was attenuated in a murine intranasal model, demonstrating the importance of A46R for VV virulence.en
dc.description.sponsorshipThis work was supported by the Irish Higher Education Authority, Enterprise Ireland, The Irish Health Research Board, and Science Foundation Ireland. G.L. Smith is a Wellcome Trust Principal Research Fellow. I.R. Haga was a CNPq (Brazil) scholar. K.A. Fitzgerald is supported by a fellowship from the Wellcome Trust, London.en
dc.format.extent1007en
dc.format.extent1018en
dc.language.isoenen
dc.relation.ispartofseriesThe Journal of Experimental Medicineen
dc.relation.ispartofseries201en
dc.relation.ispartofseries6en
dc.rightsYen
dc.subjectImmunologyen
dc.subjectToll-like receptorsen
dc.titleVaccinia virus protein A46R targets multiple Toll-like-interleukin-1 receptor adaptors and contributes to virulenceen
dc.typeJournal Articleen
dc.type.supercollectionscholarly_publicationsen
dc.type.supercollectionrefereed_publicationsen
dc.identifier.peoplefinderurlhttp://people.tcd.ie/agbowieen
dc.identifier.rssinternalid15648en
dc.identifier.doihttp://dx.doi.org/10.1084/jem.20041442en
dc.subject.TCDThemeImmunology, Inflammation & Infectionen
dc.identifier.rssurihttp://jem.rupress.org/cgi/reprint/201/6/1007en
dc.identifier.orcid_id0000-0001-5316-4373en
dc.contributor.sponsorHigher Education Authority (HEA)en
dc.identifier.urihttp://hdl.handle.net/2262/40537


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record